Targets for the treatment of erectile dysfunction: Is NO/cGMP still the answer?

Romulo Leite, Fernanda R.C. Giachini, Fernando S. Carneiro, Kênia P. Nunes, Rita C. Tostes, R Clinton Webb

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

In recent years male sexual research has increasingly centered on molecular mechanisms operating from the central nervous system to peripheral end-organ levels involved in the penile erectile response. Major progress has been made in the field, and currently a whole host of neurotransmitters, chemical effectors, growth factors, second-messenger molecules, ions, intercellular proteins, and hormones have been characterized as components of the complex physiology of erectile function. Foremost among these mediators is nitric oxide (NO), which was initially characterized as a locally released physiologic mediator of the erectile response. Impaired formation and action of NO is closely associated with erectile dysfunction (ED), which may be caused by a variety of pathogenic factors. The impact of this knowledge has been substantial, leading to the development of several NO-based medical approaches for the treatment of ED. This review will focus on recent patents and current clinical trials involving innovative pharmacological and gene therapies in the field of male-ED, particularly targeting the NO/intracellular cyclic GMP pathway, which still represents the most promising therapeutic approach to treat patients with ED.

Original languageEnglish (US)
Pages (from-to)119-132
Number of pages14
JournalRecent Patents on Cardiovascular Drug Discovery
Volume2
Issue number2
DOIs
StatePublished - Jun 1 2007

Fingerprint

Erectile Dysfunction
Nitric Oxide
Investigational Therapies
Patents
Cyclic GMP
Second Messenger Systems
Therapeutics
Genetic Therapy
Neurotransmitter Agents
Intercellular Signaling Peptides and Proteins
Central Nervous System
Clinical Trials
Hormones
Pharmacology
Ions
Research
Proteins

Keywords

  • Erectile dysfunction
  • Gene therapy
  • Growth factors
  • Ion channels
  • Nitric oxide
  • Nitric oxide synthase
  • PDE-5 inhibitors
  • Penile erection
  • RhoA/Rho-kinase
  • cGMP

ASJC Scopus subject areas

  • Drug Discovery
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Targets for the treatment of erectile dysfunction : Is NO/cGMP still the answer? / Leite, Romulo; Giachini, Fernanda R.C.; Carneiro, Fernando S.; Nunes, Kênia P.; Tostes, Rita C.; Webb, R Clinton.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 2, No. 2, 01.06.2007, p. 119-132.

Research output: Contribution to journalReview article

Leite, Romulo ; Giachini, Fernanda R.C. ; Carneiro, Fernando S. ; Nunes, Kênia P. ; Tostes, Rita C. ; Webb, R Clinton. / Targets for the treatment of erectile dysfunction : Is NO/cGMP still the answer?. In: Recent Patents on Cardiovascular Drug Discovery. 2007 ; Vol. 2, No. 2. pp. 119-132.
@article{d0077b454400413d8aabf87ab2c1a3cf,
title = "Targets for the treatment of erectile dysfunction: Is NO/cGMP still the answer?",
abstract = "In recent years male sexual research has increasingly centered on molecular mechanisms operating from the central nervous system to peripheral end-organ levels involved in the penile erectile response. Major progress has been made in the field, and currently a whole host of neurotransmitters, chemical effectors, growth factors, second-messenger molecules, ions, intercellular proteins, and hormones have been characterized as components of the complex physiology of erectile function. Foremost among these mediators is nitric oxide (NO), which was initially characterized as a locally released physiologic mediator of the erectile response. Impaired formation and action of NO is closely associated with erectile dysfunction (ED), which may be caused by a variety of pathogenic factors. The impact of this knowledge has been substantial, leading to the development of several NO-based medical approaches for the treatment of ED. This review will focus on recent patents and current clinical trials involving innovative pharmacological and gene therapies in the field of male-ED, particularly targeting the NO/intracellular cyclic GMP pathway, which still represents the most promising therapeutic approach to treat patients with ED.",
keywords = "Erectile dysfunction, Gene therapy, Growth factors, Ion channels, Nitric oxide, Nitric oxide synthase, PDE-5 inhibitors, Penile erection, RhoA/Rho-kinase, cGMP",
author = "Romulo Leite and Giachini, {Fernanda R.C.} and Carneiro, {Fernando S.} and Nunes, {K{\^e}nia P.} and Tostes, {Rita C.} and Webb, {R Clinton}",
year = "2007",
month = "6",
day = "1",
doi = "10.2174/157489007780832579",
language = "English (US)",
volume = "2",
pages = "119--132",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Targets for the treatment of erectile dysfunction

T2 - Is NO/cGMP still the answer?

AU - Leite, Romulo

AU - Giachini, Fernanda R.C.

AU - Carneiro, Fernando S.

AU - Nunes, Kênia P.

AU - Tostes, Rita C.

AU - Webb, R Clinton

PY - 2007/6/1

Y1 - 2007/6/1

N2 - In recent years male sexual research has increasingly centered on molecular mechanisms operating from the central nervous system to peripheral end-organ levels involved in the penile erectile response. Major progress has been made in the field, and currently a whole host of neurotransmitters, chemical effectors, growth factors, second-messenger molecules, ions, intercellular proteins, and hormones have been characterized as components of the complex physiology of erectile function. Foremost among these mediators is nitric oxide (NO), which was initially characterized as a locally released physiologic mediator of the erectile response. Impaired formation and action of NO is closely associated with erectile dysfunction (ED), which may be caused by a variety of pathogenic factors. The impact of this knowledge has been substantial, leading to the development of several NO-based medical approaches for the treatment of ED. This review will focus on recent patents and current clinical trials involving innovative pharmacological and gene therapies in the field of male-ED, particularly targeting the NO/intracellular cyclic GMP pathway, which still represents the most promising therapeutic approach to treat patients with ED.

AB - In recent years male sexual research has increasingly centered on molecular mechanisms operating from the central nervous system to peripheral end-organ levels involved in the penile erectile response. Major progress has been made in the field, and currently a whole host of neurotransmitters, chemical effectors, growth factors, second-messenger molecules, ions, intercellular proteins, and hormones have been characterized as components of the complex physiology of erectile function. Foremost among these mediators is nitric oxide (NO), which was initially characterized as a locally released physiologic mediator of the erectile response. Impaired formation and action of NO is closely associated with erectile dysfunction (ED), which may be caused by a variety of pathogenic factors. The impact of this knowledge has been substantial, leading to the development of several NO-based medical approaches for the treatment of ED. This review will focus on recent patents and current clinical trials involving innovative pharmacological and gene therapies in the field of male-ED, particularly targeting the NO/intracellular cyclic GMP pathway, which still represents the most promising therapeutic approach to treat patients with ED.

KW - Erectile dysfunction

KW - Gene therapy

KW - Growth factors

KW - Ion channels

KW - Nitric oxide

KW - Nitric oxide synthase

KW - PDE-5 inhibitors

KW - Penile erection

KW - RhoA/Rho-kinase

KW - cGMP

UR - http://www.scopus.com/inward/record.url?scp=34250741398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250741398&partnerID=8YFLogxK

U2 - 10.2174/157489007780832579

DO - 10.2174/157489007780832579

M3 - Review article

C2 - 18221110

AN - SCOPUS:34250741398

VL - 2

SP - 119

EP - 132

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 2

ER -